SARS-CoV-2 infection and vaccination trigger long-lived B and CD4+ T lymphocytes with implications for booster strategies

  1. Alessio Mazzoni
  2. Anna Vanni
  3. Michele Spinicci
  4. Giulia Lamacchia
  5. Seble Tekle Kiros
  6. Arianna Rocca
  7. Manuela Capone
  8. Nicoletta Di Lauria
  9. Lorenzo Salvati
  10. Alberto Carnasciali
  11. Elisabetta Mantengoli
  12. Parham Farahvachi
  13. Lorenzo Zammarchi
  14. Filippo Lagi
  15. Maria Grazia Colao
  16. Francesco Liotta
  17. Lorenzo Cosmi
  18. Laura Maggi
  19. Alessandro Bartoloni
  20. Gian Maria Rossolini
  21. Francesco Annunziato

Reviewed by

Read the full article See related articles

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1172/jci157990
  2. ScreenIT

    SciScore for 10.1101/2021.12.29.21268469: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    EthicsConsent: Written informed consent was obtained from recruited patients.
    Sex as a biological variablenot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    Evaluation of SARS-CoV-2-specific IgM and IgG: Evaluation of SARS-CoV-2 Spike protein antibodies, including anti-Spike (in trimeric form)-specific IgG (Diasorin),
    anti-Spike
    suggested: None
    RBD-specific IgG (Abbott) and IgA (Euroimmun), anti-Spike-specific IgM (Abbot), anti-Nucleoprotein-specific IgG (Abbott), and neutralizing antibodies which block binding of Spike protein with the ACE2 receptor (Dia.Pro Diagnostic Bioprobes) was performed following manufacturers’ instructions.
    anti-Spike-specific IgM ( Abbot) , anti-Nucleoprotein-specific IgG
    suggested: None
    Software and Algorithms
    SentencesResources
    Evaluation of SARS-CoV-2-Spike-reactive T cells: For T cells stimulation in vitro, 1.5 million PBMNCs were cultured in complete RPMI plus 5% human AB serum in 96 well flat bottom plates in presence of medium alone (background, negative control) or of a pool of Spike SARS-CoV-2 peptide pools (Prot_S1, Prot_S+ and Prot_S to achieve a complete sequence coverage of the Spike protein) at 0.6 µM/peptide, accordingly to manufacturer’s instructions (Miltenyi Biotech).
    Prot_S
    suggested: None
    Samples were acquired on a BD LSR II flow cytometer (BD Biosciences) with FACSDiva Software and analysed by FlowJo Software.
    FlowJo
    suggested: (FlowJo, RRID:SCR_008520)
    FACSDiva
    suggested: (BD FACSDiva Software, RRID:SCR_001456)
    Samples were acquired on a BD LSR II flow cytometer (BD Biosciences) with FACSDiva Software and analysed by FlowJo Software.
    FlowJo
    suggested: (FlowJo, RRID:SCR_008520)
    FACSDiva
    suggested: (BD FACSDiva Software, RRID:SCR_001456)
    RBD-specific IgG (Abbott) and IgA (Euroimmun), anti-Spike-specific IgM (Abbot), anti-Nucleoprotein-specific IgG (Abbott), and neutralizing antibodies which block binding of Spike protein with the ACE2 receptor (Dia.Pro Diagnostic Bioprobes) was performed following manufacturers’ instructions.
    Abbott
    suggested: (Abbott, RRID:SCR_010477)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2021.12.29.21268469v1 on medRxiv